text.skipToContent text.skipToNavigation
Pharma & Biotech

You searched for "marrow.aspx"

14 Products found

You searched for "marrow.aspx"

63 Documents found
  • Lonza Custom CellBio Services – Expand Your Research Options
  • TechSheet - PoieticsTM Osteoclast Precursor Cell System
    2T-110 OCP primary human osteoclastsPT-8001 OCP BulletKitPT-8201 OCP basal medium Osteoclast precursor basal mediumPT-9501 OCP Growth medium SingleQuots kitPA-1000 OsteoAssay human bone platePA-4490 CalciFluor assay
  • 32D Transfection Protocol - NucleofectorTM I/II/2b Device Series
    Instructions of use for transfection of 32D cells with the Cell Line NucleofectorTM Kit V
  • D1 ORL UVA Transfection Protocol - NucleofectorTM I/II/2b Device Series
    Instructions of use for transfection of D1 ORL UVA cells with the Cell Line NucleofectorTM Kit T
  • Cell-based Assays Using Hard-to-transfect Cell Lines and Transiently Transfected Primary Cells
    Co-sponsered poster with Promega
  • Instructions - AdipoRedTM Assay Reagent (PT-7009)
    PT-7009 AdipoRed Assay Reagent - Instructions for Use
  • Brochure - Cell List
    Integrated solutions for primary cells and transfection
  • Bioscience Solutions Catalog 2018
    RES_Catalog2018-Final.pdf
  • Therapeutic approaches to enhance natural killer cell cytotoxicity: the force awakens
    Poster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
  • Cell List – Integrated Solutions for Primary Cells and Transfection
  • Transfection Protocol for Human MSC - 96-well ShuttleTM Device
    Instructions of use for transfection of human mesenchymal stem cells with the P1 Primary Cell 96-well NucleofectorTM Kit
  • Transfection Protocol for Human MSC - HT NucleofectorTM Device
    Instructions of use for transfection of human mesenchymal stem cells with the P1 Primary Cells HT-NucleofectorTM Kit
  • KG-1 Transfection Protocol - 4D-NucleofectorTM Device
    Instructions of use for transfection of KG-1 cells with the SF Cell Line 4D-NucleofectorTM X Kit
  • Webinar – Primary and Stem Cell Applications for Diabetes and Obesity Research (pdf)
    Lonza_Webinars_Webinar__Primary_and_Stem_Cell_Applications_for_Diabetes_and_Obesity_Research_pdf.pdf
  • A Three-Dimensional RAFTTM Co-Culture as Advanced Model for Breast Cancer Drug Discovery
    Presented at AACR 2017, we demonstrate here the feasibility of co-culturing human mammary fibroblasts and human mammary epithelial cells in RAFTTM 3D Culture System as a 3D breast cancer model.
  • From Drug Discovery to Manufacturing – Solving Your Primary Cell Culture Challenges
    This presentation discusses how and why Lonza's primary cells and media and support team can help researchers from drug discovery to manufacturing to overcome their cell culture challenges.
  • Transfection Protocol for Human MSC - 4D-NucleofectorTM Device
    Instructions of use for transfection of human mesenchymal stem cells with the P1 Primary Cell 4D-NucleofectorTM X Kit
  • Endotoxin Testing – A Comprehensive Training Course for UK and Ireland
    History & OverviewEndotoxin Detection MethodsPractical DemonstrationUnderstanding the Data ReportEndotoxin Testing and Regulatory RequirementsCommon Assay Issues
  • Webinar – Efficient Transfection of Biologically Relevant Cells in Immunology Research (pdf)
    Lonza_Webinars_Webinar__Efficient_Transfection_of_Biologically_Relevant_Cells_in_Immunology_Research.pdf
  • CAR T cells in Cancer Therapy
    A poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.
  • 2
  • 3(current)
  • 4

You searched for "marrow.aspx"

0 Results found
We use cookies to deliver the best service to you. By continuing to browse the site, you are agreeing to our use of cookies.Ok